osteoprotegerin and Gaucher-Disease

osteoprotegerin has been researched along with Gaucher-Disease* in 2 studies

Other Studies

2 other study(ies) available for osteoprotegerin and Gaucher-Disease

Article	Year
Osteocyte Alterations Induce Osteoclastogenesis in an In Vitro Model of Gaucher Disease. International journal of molecular sciences, 2017, Jan-13, Volume: 18, Issue:1 Topics: Animals; Apoptosis; Bone Marrow Cells; Cell Differentiation; Cell Line; Connexin 43; Culture Media, Conditioned; Female; Gaucher Disease; Inositol; Integrin beta Chains; Interleukin-6; Macrophages; Mice, Inbred C57BL; Models, Biological; Osteoclasts; Osteocytes; Osteogenesis; Osteoprotegerin; RANK Ligand; Solubility	2017
Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease. British journal of haematology, 2006, Volume: 133, Issue:1 Bone involvement in Gaucher disease causes disability and reduced quality of life; loss of function and pain are important indications for enzyme replacement therapy. The purpose of this study was to ascertain whether osteoprotegerin (OPG), which decreases osteoclast activity, is indicative of incipient bone involvement by comparing OPG serum levels to Gaucher disease severity (SSI) and bone mineral density (BMD), and to correlate bone and disease markers to OPG polymorphisms: OPG1-2(A163G), OPG3-4(T129C) and OPG5-6(C1217T). Of 554 patients, 173 Ashkenazi Jewish patients with non-neuronopathic Gaucher disease were enrolled and 32 healthy Ashkenazi Jews served as controls. Serum OPG levels were detected by enzyme-linked immunosorbent assay and BMD was obtained by dual X-ray absorptiometry. OPG polymorphisms were determined in 63 randomly chosen patients. Serum OPG values for patients were not greater than in controls, but showed a statistically significant trend to increase with age (P = 0.057). No correlation existed between OPG levels and BMD or with genotype or other disease markers. A significant correlation was noted between OPG5-6 genotype and SSI. A significant difference was found between the allele distributions of each OPG polymorphism when compared with Caucasians and Ashkenazi Jews. OPG levels probably do not predict BMD in Gaucher disease and hence are not indicative of osteoporosis in Gaucher disease. Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density; Case-Control Studies; Child; Child, Preschool; Female; Gaucher Disease; Genotype; Glycoproteins; Humans; Jews; Male; Middle Aged; Osteoprotegerin; Phenotype; Polymorphism, Genetic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor	2006

Article

Year

Osteocyte Alterations Induce Osteoclastogenesis in an In Vitro Model of Gaucher Disease.

International journal of molecular sciences, 2017, Jan-13, Volume: 18, Issue:1

Topics: Animals; Apoptosis; Bone Marrow Cells; Cell Differentiation; Cell Line; Connexin 43; Culture Media, Conditioned; Female; Gaucher Disease; Inositol; Integrin beta Chains; Interleukin-6; Macrophages; Mice, Inbred C57BL; Models, Biological; Osteoclasts; Osteocytes; Osteogenesis; Osteoprotegerin; RANK Ligand; Solubility

2017

Serum levels of osteoprotegerin and osteoprotegerin polymorphisms in Gaucher disease.

British journal of haematology, 2006, Volume: 133, Issue:1

Bone involvement in Gaucher disease causes disability and reduced quality of life; loss of function and pain are important indications for enzyme replacement therapy. The purpose of this study was to ascertain whether osteoprotegerin (OPG), which decreases osteoclast activity, is indicative of incipient bone involvement by comparing OPG serum levels to Gaucher disease severity (SSI) and bone mineral density (BMD), and to correlate bone and disease markers to OPG polymorphisms: OPG1-2(A163G), OPG3-4(T129C) and OPG5-6(C1217T). Of 554 patients, 173 Ashkenazi Jewish patients with non-neuronopathic Gaucher disease were enrolled and 32 healthy Ashkenazi Jews served as controls. Serum OPG levels were detected by enzyme-linked immunosorbent assay and BMD was obtained by dual X-ray absorptiometry. OPG polymorphisms were determined in 63 randomly chosen patients. Serum OPG values for patients were not greater than in controls, but showed a statistically significant trend to increase with age (P = 0.057). No correlation existed between OPG levels and BMD or with genotype or other disease markers. A significant correlation was noted between OPG5-6 genotype and SSI. A significant difference was found between the allele distributions of each OPG polymorphism when compared with Caucasians and Ashkenazi Jews. OPG levels probably do not predict BMD in Gaucher disease and hence are not indicative of osteoporosis in Gaucher disease.

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density; Case-Control Studies; Child; Child, Preschool; Female; Gaucher Disease; Genotype; Glycoproteins; Humans; Jews; Male; Middle Aged; Osteoprotegerin; Phenotype; Polymorphism, Genetic; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor

2006